Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov;14(4):363-370.
doi: 10.20892/j.issn.2095-3941.2017.0099.

Camptothecin-based nanodrug delivery systems

Yan Wen  1   2 , Yingze Wang  1 , Xiaoli Liu  1 , Wei Zhang  1 , Xinhe Xiong  1 , Zhongxiao Han  1 , Xingjie Liang  1   2
Affiliations

Camptothecin-based nanodrug delivery systems

Yan Wen et al. Cancer Biol Med. 2017 Nov.

Abstract

The drug camptothecin has a wide range of antitumor effects in cancers including gastric cancer, rectal and colon cancer, liver cancer, and lung cancer. Camptothecin-based drugs inhibit topoisomerase 1 (Topo 1), leading to destruction of DNA, and are currently being used as important chemotherapeutic agents in clinical antitumor treatment. However, the main obstacle associated with cancer therapy is represented by systemic toxicity of conventional anticancer drugs and their low accumulation at the tumor site. In addition, low bioavailability, poor water solubility, and other shortcomings hinder their anticancer activity. Different from traditional pharmaceutical preparations, nanotechnology-dependent nanopharmaceutical preparations have become one of the main strategies for different countries worldwide to overcome drug development problems. In this review, we summarized the current hotspots and discussed a variety of camptothecin-based nanodrugs for cancer therapy. We hope that through this review, more efficient drug delivery systems could be designed with potential applications in clinical cancer therapy.

Keywords: Camptothecins; cancer therapy; drug delivery system; nanomedicine.

PubMed Disclaimer

Figures

1
1
Schematic illustration of established camptothecins-based nanodrug platforms.
2
2
Schematic structure of NK012 and release of SN-38 from NK012. Reprinted with permission from Ref [23]; Copyright © 2010, American Association for Cancer Research.
See this image and copyright information in PMC

References

    1. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata . J Am Chem Soc. 1966;88:3888–90.
    1. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985;260:14873–8. - PubMed
    1. Wall ME. Camptothecin and taxol: discovery to clinic. Med Res Rev. 1998;18:299–314. - PubMed
    1. O’Leary J, Muggia FM. Camptothecins: a review of their development and schedules of administration. Eur J Cancer. 1998;34:1500–8. - PubMed
    1. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res. 1994;54:1431–9. - PubMed